AR128825A1 - Composiciones farmacéuticas de esfingomielinasa ácida humana recombinante y métodos - Google Patents

Composiciones farmacéuticas de esfingomielinasa ácida humana recombinante y métodos

Info

Publication number
AR128825A1
AR128825A1 ARP230100671A ARP230100671A AR128825A1 AR 128825 A1 AR128825 A1 AR 128825A1 AR P230100671 A ARP230100671 A AR P230100671A AR P230100671 A ARP230100671 A AR P230100671A AR 128825 A1 AR128825 A1 AR 128825A1
Authority
AR
Argentina
Prior art keywords
rasm
methods
acid sphingomyelinase
chromatography
cex
Prior art date
Application number
ARP230100671A
Other languages
English (en)
Spanish (es)
Inventor
Thomas M Wasylenko
Kevin Brower
Xiaoying Jin
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR128825A1 publication Critical patent/AR128825A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ARP230100671A 2022-03-18 2023-03-17 Composiciones farmacéuticas de esfingomielinasa ácida humana recombinante y métodos AR128825A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263321636P 2022-03-18 2022-03-18

Publications (1)

Publication Number Publication Date
AR128825A1 true AR128825A1 (es) 2024-06-19

Family

ID=86051983

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100671A AR128825A1 (es) 2022-03-18 2023-03-17 Composiciones farmacéuticas de esfingomielinasa ácida humana recombinante y métodos

Country Status (12)

Country Link
US (1) US20230365946A1 (cg-RX-API-DMAC7.html)
EP (1) EP4493684A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509722A (cg-RX-API-DMAC7.html)
KR (1) KR20240156645A (cg-RX-API-DMAC7.html)
CN (1) CN119365593A (cg-RX-API-DMAC7.html)
AR (1) AR128825A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023235321A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254814A1 (cg-RX-API-DMAC7.html)
IL (1) IL315655A (cg-RX-API-DMAC7.html)
MX (1) MX2024011382A (cg-RX-API-DMAC7.html)
TW (1) TW202403043A (cg-RX-API-DMAC7.html)
WO (1) WO2023178325A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119968454A (zh) 2022-09-28 2025-05-09 建新公司 用于生产生物产品的系统和装置及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US20020137173A1 (en) * 2001-02-05 2002-09-26 Dae-Kyong Kim Membrane-associated sphingomyelinase derived from bovine brain, isolation method therefor and anti-sphingomyelinase monoclonal anitibody
BRPI0411291A (pt) * 2003-06-12 2006-08-01 Genzyme Corp esfingomielinase acida humana modificada tendo atividade aumentada e métodos para a fabricação da mesma
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
CN101918430A (zh) 2008-01-18 2010-12-15 弗·哈夫曼-拉罗切有限公司 非糖基化蛋白质的纯化
KR20130020789A (ko) 2010-05-19 2013-02-28 에프. 호프만-라 로슈 아게 소수성 상호작용 크로마토그래피 방법
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US10259842B2 (en) 2013-05-15 2019-04-16 Medimmune, Llc Purification of recombinantly produced polypeptides
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy
EP3728287B1 (en) 2017-12-19 2024-04-10 CSL Behring Lengnau AG Protein purification and virus inactivation with alkyl glycosides
PY1939780A (es) 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida

Also Published As

Publication number Publication date
TW202403043A (zh) 2024-01-16
KR20240156645A (ko) 2024-10-30
WO2023178325A1 (en) 2023-09-21
AU2023235321A1 (en) 2024-10-31
MX2024011382A (es) 2024-09-23
CN119365593A (zh) 2025-01-24
EP4493684A1 (en) 2025-01-22
JP2025509722A (ja) 2025-04-11
IL315655A (en) 2024-11-01
CA3254814A1 (en) 2023-09-21
US20230365946A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
Gutiérrez et al. Pharmacological activities of a toxic phospholipase A isolated from the venom of the snake Bothrops asper
Terlecky et al. Polypeptide import and degradation by isolated lysosomes.
de La Salle et al. Active γ-carboxylated human factor IX expressed using recombinant DNA techniques
Rodrigues et al. Geographic variations in the composition of myotoxins from Bothrops neuwiedi snake venoms: biochemical characterization and biological activity
Rodrigues et al. Bactericidal and neurotoxic activities of two myotoxic phospholipases A2 from Bothrops neuwiedi pauloensis snake venom
Schengrund et al. Sialidase activity in transformed cells
Bidney et al. Purification from cultured hepatoma cells of two nonhistone chromatin proteins with preferential affinity for single-stranded DNA: apparent analogy with calf thymus HMG proteins
JP2005520550A (ja) 所望エリスロポエチングリコアイソフォームプロフィールの製造方法
Kanashiro et al. Biochemical and biological properties of phospholipases A2 from Bothrops atrox snake venom
Wahby et al. Egyptian horned viper Cerastes cerastes venom hyaluronidase: Purification, partial characterization and evidence for its action as a spreading factor
Suttie The metabolic role of vitamin K
WO1998038318A1 (de) Faktor x-deletionsmutanten und analoge davon
CA2569465A1 (en) Method for purifying erythropoietin
DE68915226T2 (de) Thrombin bindende Substanz und Verfahren zu ihrer Herstellung.
Venkatesh et al. Synergistically acting PLA2: Peptide hemorrhagic complex from Daboia russelii venom
EP0354354B1 (de) Verfahren zur Anreicherung der Blutgerinnungsfaktoren II, VII, IX und X
Duplat et al. The effect of molecules in mother-of-pearl on the decrease in bone resorption through the inhibition of osteoclast cathepsin K
Dias et al. BaltPLA2: a new phospholipase A2 from Bothrops alternatus snake venom with antiplatelet aggregation activity
KR101853463B1 (ko) 보툴리눔 독소의 정제 방법
Lomonte et al. Antibody neutralization of a myotoxin from the venom of Bothrops asper (terciopelo)
Shashidharamurthy et al. A neurotoxic phospholipase A2 variant: Isolation and characterization from eastern regional Indian cobra (Naja naja) venom
Ponce-Soto et al. Neurotoxic, myotoxic and cytolytic activities of the new basic PLA2 isoforms BmjeTX-I and BmjeTX-II isolated from the Bothrops marajoensis (marajó lancehead) snake venom
JP2025509722A5 (cg-RX-API-DMAC7.html)
MX2024011382A (es) Composiciones y metodos farmaceuticos de esfingomielinasa acida humana recombinante.
JPS59155324A (ja) ヒト尿中チオ−ルプロテア−ゼインヒビタ−を有効成分とする抗炎症剤及びその製造法